Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-05-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物关于完成公司经营范围变更的工商登记并换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company about the completion of a change in its business scope and the corresponding update of its business license. It references board and shareholder approvals for these changes and notes the filing and registration with the local market supervision bureau. The document does not contain financial statements, audit information, or detailed financial data. It is a regulatory announcement about corporate administrative changes rather than a financial report or management discussion. The document length is short (1231 characters) and it serves as a formal notice of completed administrative changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-22 Chinese
前沿生物公司章程（2023年5月南京市市场监督管理局备案版）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Frontier Biotechnologies Inc. It contains detailed company governance rules, shareholder rights and obligations, board and management structure, share issuance and transfer rules, and procedures for shareholder meetings. It references relevant laws and regulations such as the Company Law and Securities Law, and includes detailed chapters on company organization and governance practices. There is no financial data, earnings information, or audit results presented. The document is a governance framework document, not a financial report or announcement. Therefore, it fits the category of Governance Information (CGR).
2023-05-22 Chinese
前沿生物2023年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第一季度报告' which translates to '2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The report is unaudited as indicated. The content includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, specifically a quarter. This matches the definition of an Interim / Quarterly Report (IR). The document length is over 12,000 characters and contains substantive financial data, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2023
2023-04-28 Chinese
国浩律师（南京）事务所关于前沿生物药业（南京）股份有限公司2022年年度股东大会的法律意见书
Regulatory Filings
2023-04-27 Chinese
前沿生物2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of the company 前沿生物药业（南京）股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including the 2022 annual report, financial reports, profit distribution plan, and other corporate matters. The document also contains legal witness statements confirming the validity of the meeting and voting process. The content is focused on the official voting results and decisions made at the AGM rather than the full annual report or financial statements themselves. The document length is 4225 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-04-27 Chinese
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司2022年持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022 Year Continuous Supervision Work On-Site Inspection Report" by CITIC Securities for a listed company, Frontier Biopharmaceuticals (Nanjing) Co., Ltd. It details the on-site inspection activities, including governance, internal control, information disclosure, independence, use of raised funds, related party transactions, and operational status during the continuous supervision period. The document is a report by the sponsor institution fulfilling regulatory continuous supervision duties, not a full annual report or audit report. It is a standalone audit-related report focusing on compliance and regulatory inspection results, consistent with an Audit Report / Information filing. The document length is under 5,000 characters, but it contains substantive content and is not merely an announcement or certification. Therefore, it fits best under the Audit Report / Information (AR) category. FY 2022
2023-04-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.